Akero Therapeutics (NASDAQ:AKRO) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Akero Therapeutics (NASDAQ:AKRO) in a research note published on Thursday morning, Benzinga reports.

Several other research firms have also recently commented on AKRO. Canaccord Genuity Group lowered their target price on shares of Akero Therapeutics from $59.00 to $56.00 and set a buy rating for the company in a research note on Monday, May 13th. Evercore ISI lowered their target price on shares of Akero Therapeutics from $50.00 to $38.00 and set an outperform rating for the company in a research note on Wednesday, May 15th. Wolfe Research initiated coverage on shares of Akero Therapeutics in a research note on Tuesday, June 11th. They issued an outperform rating for the company. HC Wainwright reaffirmed a buy rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Tuesday, June 11th. Finally, UBS Group lifted their target price on shares of Akero Therapeutics from $39.00 to $42.00 and gave the stock a buy rating in a research note on Tuesday, March 5th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $41.13.

Akero Therapeutics Trading Down 1.7 %

Shares of AKRO opened at $21.78 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 30.12 and a quick ratio of 30.12. The firm has a 50 day simple moving average of $20.80 and a 200-day simple moving average of $22.46. Akero Therapeutics has a 1-year low of $11.25 and a 1-year high of $54.35. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -6.81 and a beta of -0.31.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, May 10th. The company reported ($0.90) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.90). Equities analysts forecast that Akero Therapeutics will post -3.82 EPS for the current fiscal year.

Insider Activity at Akero Therapeutics

In related news, COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $24.38, for a total transaction of $121,900.00. Following the transaction, the chief operating officer now owns 263,306 shares in the company, valued at approximately $6,419,400.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $24.38, for a total transaction of $121,900.00. Following the transaction, the chief operating officer now owns 263,306 shares in the company, valued at approximately $6,419,400.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Catriona Yale sold 2,825 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $22.64, for a total transaction of $63,958.00. Following the completion of the transaction, the insider now owns 74,867 shares in the company, valued at approximately $1,694,988.88. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,635 shares of company stock worth $695,716. 7.94% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Akero Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Quarry LP grew its position in shares of Akero Therapeutics by 40.0% during the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock valued at $41,000 after buying an additional 500 shares during the last quarter. Orion Capital Management LLC acquired a new position in Akero Therapeutics during the 3rd quarter valued at about $51,000. Strs Ohio boosted its stake in Akero Therapeutics by 100.0% during the 4th quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $46,000 after purchasing an additional 1,000 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Akero Therapeutics by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after purchasing an additional 1,030 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in Akero Therapeutics by 2,366.0% during the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after purchasing an additional 1,183 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.